## Abstract There is emerging data supporting the use of TTS‐F (transdermal therapeutic system‐fentanyl) in opioid naive patients. Our study examines the safety and efficacy of TTS‐F in the long‐term control of cancer pain in opioid naive patients and those transferring from oral morphine. Pain was
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain
✍ Scribed by Miguel Angel Benítez-Rosario; Manuel Feria; Antonio Salinas-Martín; Luis Pedro Martínez-Castillo; José Javier Martín-Ortega
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 169 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## BACKGROUND. When a change of opioid is considered, equianalgesic dose tables are used. These tables generally propose a dose ratio of 5:l between morphine and hydromorphone. In the case of a change from subcutaneous hydromorphone to methadone, dose ratios ranging from 1:6 to 1:10 are proposed.
## Abstract ## BACKGROUND The delayed effects (12–16 hours) of transdermal fentanyl make dose titration difficult during acute exacerbations of cancer pain. Patients at the authors' institution routinely are switched from transdermal to intravenous (IV) fentanyl using a 1:1 (transdermal:IV) conver
## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral